Current Edition

COVID-19 and its Ripple Effect on Clinical Trials

Whilst pandemics are fortunately not common, the global impact of COVID-19 has been profound. At the time of writing, global deaths have
reached 420,000 whilst over 7.5 million people have been infected. Sofie Vandevyver, Daniel Tanner and Mario Papillon at Cerba Research reflect on the impact on clinical trials, drug and diagnostic development and how the clinical trial market has rapidly adjusted to the new paradigm